risedronate / Generic mfg. - LARVOL DELTA

Cardiovascular Safety Signals of Osteoporosis Therapies: A FAERS Pharmacovigilance Study. (PubMed, Mediterr J Rheumatol) - "We conducted a retrospective pharmacovigilance analysis of FAERS reports between January 2019 and December 2024, identifying all reports involving alendronate, risedronate, zoledronic acid, denosumab, teriparatide, abaloparatide, or romosozumab. Romosozumab and zoledronic acid demonstrated prominent cardiovascular disproportionality signals in FAERS, whereas denosumab, abaloparatide, and teriparatide showed more favorable reporting profiles. These findings should not discourage osteoporosis treatment but underscore the importance of individualised cardiovascular risk assessment and the need for further prospective evaluation to inform safe therapy selection."

Adverse events • Journal • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • Osteoporosis • Rheumatology

Bioequivalence evaluation of risedronate sodium in healthy Chinese participants under fasting conditions: a randomized, open-label, single-dose, three-period, partial replicate crossover study. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - P=N/A | "These findings demonstrate that the test and reference formulations of risedronate sodium 35 mg tablets are bioequivalent under fasting conditions and exhibit comparable safety profiles. Clinical Trial Registration: CTR20201946."

Journal • Orthopedics • Osteoporosis • Rheumatology

Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis (clinicaltrials.gov) - P=N/A | N=40 | Completed | Sponsor: Khyber Medical University Peshawar | Recruiting ➔ Completed

Trial completion • Osteoporosis • Rheumatology

Effectiveness of Anti-Osteoporotic Medications in the Management of Glucocorticoid-Induced Osteoporosis: A Systematic Review and Network Meta-Analysis on Behalf of the ECTS Clinical Action Group. (PubMed, Eur J Endocrinol) - "This network-meta-analysis demonstrates a clear gradient of efficacy among AOM in GIOP, with anabolic and potent antiresorptive-medications producing the largest gains in lumbar- spine aBMD supporting current ECTS recommendations advocating risk-stratified treatment selection."

Journal • Retrospective data • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

A multicenter, open-label, single-arm clinical trial to evaluate the efficacy and safety of risedronate after denosumab discontinuation in postmenopausal osteoporosis women (ASBMR 2026) - No abstract available

Clinical • Osteoporosis • Rheumatology

A multicenter, open-label, single-arm clinical trial to evaluate the efficacy and safety of risedronate after denosumab discontinuation in postmenopausal osteoporosis women (ASBMR 2026) - No abstract available

Clinical • Osteoporosis • Rheumatology

The cost-effectiveness of biosimilar denosumab in postmenopausal osteoporosis: implications of baseline fracture risk and drug price. (PubMed, Osteoporos Int) - "With sufficient price reductions, biosimilar denosumab is a dominant strategy across varying levels of baseline fracture risk. Biosimilar denosumab's superior efficacy and favorable safety profile compared to bisphosphonates, along with anticipated price declines, support its potential as a first-line therapy for women with PMO at high-risk of fracture in the US."

HEOR • Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

In situ-formed multifunctional nanozyme hydrogel for synergistic radio-immunotherapy of osteosarcoma. (PubMed, Mikrochim Acta) - "A dual enzyme-mimicking nanozyme coordinated to risedronate sodium and encapsulated in a sodium alginate gel (RZRSA) was developed to enhance the radiosensitivity of osteosarcoma...In addition, radiosensitization by RZRSA triggered a robust immunogenic cell death effect and promoted dendritic cell maturation. This innovative design of RZRSA provides a promising strategy for targeted osteosarcoma treatment."

IO biomarker • Journal • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • CAT

Audit of osteoporosis risk assessment and management in patients admitted with decompensated liver cirrhosis (BSG 2026) - "Four of these patients were treated with a single dose of intravenous (IV) risedronate prior to discharge...An inpatient bone protection pathway was thus formulated to risk stratify and treat patients (as per NOGG recommendations) as an A6 sticker ( figure 1 ) to fit within paper notes. Download figure Open in new tab Download powerpoint Abstract P110 Figure 1"

Clinical • Fibrosis • Gastroenterology • Hepatology • Immunology • Liver Cirrhosis • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Efficacy of Anti-Osteoporotic Drugs and Vitamin D/calcium Supplementation in NMD: A Systematic Review (ICNMD 2026) - "Among anti-osteoporotic agents, zoledronate was most commonly employed (37.9%), followed by pamidronate (20.6%) and alendronate (17.2%)...Risedronate and neridronate did not demonstrate consistent benefits. Limited evidence suggested denosumab effectively improved BMD in small patient samples, whereas teriparatide maintained stable BMD values. This analysis highlights a lack of data on bone health management in NMD, particularly regarding specific age groups and rarer subtypes... This analysis highlights a lack of data on bone health management in NMD, particularly regarding specific age groups and rarer subtypes. These gaps emphasize the necessity of a targeted, evidence-based approach to prevent and treat bone loss. Early therapeutic interventions, guided by the biological rationale of anti-osteoporotic agents, represent a critical strategy to optimize bone health in NMD, in order to preserve functional capacity, skeletal integrity, and quality of life."

Clinical • Review • CNS Disorders • Duchenne Muscular Dystrophy • Genetic Disorders • Movement Disorders • Muscular Atrophy • Muscular Dystrophy • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rare Diseases

Effect of bisphosphonates on orthodontic tooth movement: an umbrella review. (PubMed, BMC Oral Health) - "Available evidence, derived predominantly from animal studies, consistently indicates that BPs reduce OTM. Human evidence remains very limited and is insufficient to support firm clinical recommendations. Well-designed prospective human studies are needed to clarify the clinical implications of BP use during orthodontic treatment."

Journal • Review • Orthopedics • Osteoporosis • Rare Diseases • Rheumatology • TNFRSF11B

Effect of the COVID-19 Pandemic on Treatment Strategies for Secondary Prevention of Hip Fragility Fractures. (PubMed, Isr Med Assoc J) - "The COVID-19 pandemic reduced the rate of appropriate treatment initiation following hip fractures. However, adherence to timely treatment within 3 months of the fracture has improved. The findings highlight the effectiveness of the health system response in managing crises and ensuring the timely delivery of critical treatment."

Journal • Retrospective data • Infectious Disease • Musculoskeletal Diseases • Novel Coronavirus Disease • Orthopedics • Osteoporosis • Respiratory Diseases • Rheumatology

Efficacy of romosozumab followed by denosumab in glucocorticoid users; a randomized clinical trial. (PubMed, Osteoporos Int) - "Sequential treatment with ROMO followed by DMAb increased lumbar spine BMD more than DMAb or BP alone up to 36 months, demonstrating the efficacy of this treatment strategy."

Clinical • Journal • Osteoporosis • Rheumatology • COL1A2 • TRAP

The Effects of Bisphosphonates Used in Osteoporosis Treatment on Breast Cancer: Analysis with Integrative Bioinformatics Methods, DFT, ADMET and Molecular Docking Analysis. (PubMed, Biology (Basel)) - "This study evaluated the structural, electronic, pharmacokinetic, and receptor-binding properties of three bisphosphonate derivatives, alendronate, risedronate, and zoledronate, to investigate their therapeutic relevance in osteoporosis and breast cancer. Network analyses highlighted pathways related to mevalonate metabolism, hormone signaling, angiogenesis, extracellular matrix remodeling, and the RANK/RANKL/OPG axis. These findings support the potential repurposing of bisphosphonates, particularly zoledronate, for breast cancer-associated bone disease."

Journal • Breast Cancer • Oncology • Rheumatology • Solid Tumor • BRCA2 • ER • FDPS • KDR • MMP9 • TNFSF11

Osteoporosis as a common comorbidity in sarcoidosis : results from a transversal prospective study on 101 patients with treated sarcoidosis. (EULAR 2026) - "Treatments started after evaluation were zoledronate (62%), teriparatide (12,5%) and risedronate (25%). In addition to classical risk factors, impaired pulmonary function is independently associated with osteoporosis. These findings confirm that osteoporosis is a frequent but not-enough treated comorbidity in sarcoidosis and underline the need for systematic bone assessment and improved preventive strategies in this population."

Clinical • Addiction (Opioid and Alcohol) • Immunology • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • Sarcoidosis

Study to Assess Bone after Risedronate in ESKDnSABREn: Do bisphosphonate medications improve bone health in patients on dialysis (ANZCTR) - P3 | N=114 | Active, not recruiting | Sponsor: Westmead Hospital Research and Education Network | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Chronic Kidney Disease • Musculoskeletal Diseases • Nephrology • Orthopedics • Renal Disease

Renal Outcomes and Dosage Considerations Associated with Bisphosphonate Use: A Systematic Review of Randomized Clinical Trials. (PubMed, Res Sq) - "Further, random effects model (100% (-0.01)) was performed due to high level of heterogeneity and it indicated that ibandronate 27.93%; alendronate 28.58%; risedronate 27.80% and zoledronate 15.69%. Conclusion The evidence from this review suggests that the bisphosphonates are generally well-tolerated with ten trials registering no drug-related withdrawals and other studies showing only very negligible withdrawals due to adverse effects. Even though bisphosphonates are safer to use in compromised renal function i.e., > 30ml/min/1.73m 2 , more cohort studies are required to identify bisphosphonates effects in end stage renal disease (eGFR < 15ml/min/1.73m 2 )."

Clinical • Journal • Chronic Kidney Disease • Nephrology • Orthopedics • Osteoporosis • Renal Disease • Rheumatology • Transplantation

In silico and in vitro evaluation of risedronate as a DKK1 antagonist: Implications for neuroprotection through DKK1-LRP6 modulation. (PubMed, Eur J Pharmacol) - "Risedronate demonstrates potential inhibitory effects on DKK1 in in vitro and in silico models. By bridging bone pharmacology and neurobiology, this study provides a mechanistically grounded repurposing strategy to counteract Wnt signaling failure in neurodegenerative disorders."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • DKK1

Adverse Gastrointestinal Effects of Alendronate Versus Risedronate in Osteoporosis: A Systematic Review and Meta-analysis. (PubMed, Ann Afr Med) - "In this review, the incidence rate of alendronate-associated gastrointestinal (GI) adverse effects was slightly higher than the incidence rate of risedronate-associated GI adverse effects. Although the finding is not statistically significant, switching the patient from alendronate to risedronate may nevertheless lower the incidence rate of GI side effects."

Journal • Retrospective data • Gastrointestinal Disorder • Osteoporosis • Rheumatology

A Comparison Between Bisphosphonates and Teriparatide in the Treatment of Postmenopausal Osteoporosis: A Systematic Review. (PubMed, Cureus) - "Teriparatide significantly lowered vertebral fracture risk compared with risedronate in patients with severe osteoporosis and increased lumbar spine BMD to a comparable extent as alendronate, though via a distinct anabolic mechanism. Combination therapy with zoledronic acid resulted in greater BMD gains than either agent alone...Network meta-analyses indicate that romosozumab may achieve greater early spine BMD gains than teriparatide...Anabolic agents, including teriparatide, are recommended as first-line therapy for patients at very high risk of fractures (e.g., very low BMD with prevalent fractures or fractures occurring during glucocorticoid therapy), followed by a transition to antiresorptive therapy. Treatment selection should be guided by guideline-based risk stratification rather than applying a uniform stepwise approach."

Journal • Review • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Effects of Bisphosphonates on OI-Related Hearing Loss (clinicaltrials.gov) - P4 | N=100 | Recruiting | Sponsor: Hospital for Special Surgery, New York | Trial completion date: Jan 2026 ➔ Jan 2027 | Trial primary completion date: Jan 2026 ➔ Jan 2027

Trial completion date • Trial primary completion date • Genetic Disorders • Otorhinolaryngology

Fragility fracture, atypical femoral fracture, and osteonecrosis of jaw after bisphosphonate prescription for three and five years, based on primary and secondary care data in England: nested case-control and cohort studies. (PubMed, BMJ Med) - "Adults aged ≥18 years on the date of the first prescription of alendronate or risedronate, and with primary care data linked to Hospital Episode Statistics and Office for National Statistics databases. Fragility fracture was not associated with interruption of bisphosphonate prescription for up to two years, after either three or five years of prescription. The incidence of atypical femoral fracture or osteonecrosis of jaw was uncommon and rare respectively."

Journal • Musculoskeletal Diseases • Orthopedics • Rheumatology

Efficacy and Mechanism of Camrelizumab in Combination with Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study (ChiCTR) - P=N/A | N=30 | Sponsor: Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital

New trial • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • PGR

Comparative efficacy and safety of antiresorptive and anabolic therapies for male osteoporosis: an updated Bayesian network meta-analysis. (PubMed, Front Endocrinol (Lausanne)) - "Randomized controlled trials (RCTs) evaluating alendronate, risedronate, zoledronic acid, denosumab, teriparatide, or abaloparatide were identified from PubMed, Web of Science, and the Cochrane Library through 2025. Safety outcomes were comparable across drug classes, suggesting that treatment choice should primarily be guided by efficacy considerations. https://www.crd.york.ac.uk/prospero/, identifier CRD420251151177."

Clinical • Journal • Retrospective data • Review • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Cost-Effectiveness of Biosimilar Denosumab Versus Bisphosphonates in Postmenopausal Osteoporosis. (PubMed, Pharmacoecon Open) - "Biosimilar denosumab was estimated to be cost-effective compared with alendronate, risedronate, ibandronate, and zoledronic acid at a WTP threshold of $150,000/QALY gained and compared with risedronate at a threshold of $100,000/QALY gained. As a lower-cost alternative to reference denosumab, biosimilar denosumab may enhance patient access to effective PMO treatment in the USA."

HEOR • Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology